<DOC>
	<DOC>NCT01202630</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of BIO-K+ CL1285 for prevention of recurrent Clostridium difficile infection.</brief_summary>
	<brief_title>BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>1. Age 18 years or older 2. Presence of two or more loose or liquid stools in the 24hour period prior to initiation of antibiotic therapy 3. Hospitalized and starting antibiotic therapy for Clostridium difficile infection (CDI) or recurrent Clostridium difficile infection (RCDI), diagnosed with a positive stool culture 4. Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only) 5. Understand the nature and purpose of the study including potential risks and side effects 6. Willing to comply with the requirements of the study 1. History of 2 or more clostridium difficile infections at any time prior to the current episode 2. Presence of severe chronic and/or inflammatory condition 3. Impaired immunity, e.g. undergoing immunotherapy or chemotherapy 4. Major gastrointestinal complication, e.g. Crohn's disease or ulcer 5. Current treatment with nasogastric tube, ostomy, or parenteral nutrition 6. Use of proton pump inhibitors 7. Pregnant female or breastfeeding 8. Eating disorder 9. History of alcohol, drug, or medication abuse 10. Daily consumption of probiotics, fermented milk, and/or yogurt 11. Known allergies to any substance in the study product 12. Participation in another study with any investigational product within 3 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>diarrhea</keyword>
</DOC>